Interferon-α in acute posttransfusion hepatitis C:. A randomized, controlled trial
✍ Scribed by Lluis Viladomiu; Dr. Joan Genescà; Juan I. Esteban; Helena Allende; Antonio González; Juan Carlos López-Talavera; Rafael Esteban; Jaime Guardia
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 372 KB
- Volume
- 15
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Chronic hepatitis C is often a progressive liver disease for which there is no satisfactory treatment. We studied the efficacy of recombinant a-interferon or y-interferon in the treatment of this disease in comparison with a control group. Thirty patients were randomly assigned to three groups. Ten
In chronic hepatitis C virus (HCV) infection, the rate of sustained response to interferon is low. We evaluated, in patients responding to a 26-week course of interferon, the effect of high-dose maintenance therapy in preventing relapse. Three hundred and ten patients with chronic HCV infection (38.
AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC
The role of antivirals in patients with acute viral hepatitis B (AVH-B) has not been evaluated in controlled trials. The aim of this study was to evaluate the efficacy of lamivudine in patients with AVH-B. AVH-B patients with serum bilirubin of more than 5 mg/dL were randomized to receive either 100